Poll

Poll results: Will you use biosimilars in your ophthalmic practice?

Results from our recent poll indicate that many ophthalmologists (63%) plan to use biosimilars in their clinical practice.

Ophthalmology Times® polled our audience with the following question from September 26, 2022 to October 10, 2022:​ Will you use biosimilars in your ophthalmic practice?

The poll appeared on OphthalmologyTimes.com and was promoted in our e-newsletters during this time. Results show a majority of ophthalmologists plan to use biosimilars in their practice.

37 responses were recorded, in total. Of these:

23% responded, "Yes, I plan to use biosimilars in my practice."

14% responded, "No, I do not plan to use biosimilars in my practice."

.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Jason Bacharach, MD, on early-onset efficacy with perfluorohexyloctane in dry eye
(Image credit: Ophthalmology Times) CCOI's new CEO Malvina Eydelman, MD, outlines her mission and vision for the organization
(Image credit: Ophthalmology Times) ASCRS 2025: Deb Ristvedt, DO, on medications, lasers, and lifestyle in glaucoma management
© 2025 MJH Life Sciences

All rights reserved.